(1) Background: This study comprehensively compared robotic pancreatic surgery with vascular resection (RPS-VR) to other surgical procedures in the treatment of pancreatic ductal adenocarcinoma (PDAC). (2) Methods: A systematic review of relevant literature was conducted to assess a range of crucial surgical and oncological outcomes. (3) Results: Findings indicate that robotic surgery with vascular resections (VRs) significantly prolongs the duration of surgery compared to other surgical procedures, and they notably demonstrate an equal hospital stay. While some studies reported a lower conversion rate and a higher rate of blood loss and blood transfusion in the RPS-VR group, others found no significant disparity. Furthermore, RPS-VR consistently correlated with comparable recurrence rates, free margins R0, postoperative mortality, and complication rates. Concerning the last one, certain reviews reported a higher rate of major complications. Overall survival and disease-free survival remained comparable between the RPS-VR and other surgical techniques in treating PDAC. (4) Conclusions: The analysis emphasizes how RPS-VR is a resembling approach in terms of surgical outcomes and aligns with existing literature findings in this field.

Background: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer with substantial mortality and limited prognostic granularity under current staging systems. Artificial intelligence (AI) has shown promise across oncology, but no synthesis has yet evaluated its application specifically to MCC across the clinical continuum, from detection to survival prediction. Methods: This systematic review followed PRISMA and Cochrane guidelines and was prospectively registered with PROSPERO. Four databases (PubMed, Embase, Scopus, and CENTRAL) were searched from inception through June 18, 2026. Eligible studies evaluated AI, machine learning, or computational models using human MCC data. Given anticipated heterogeneity in predictive targets and metrics, a narrative synthesis was performed. Results: Of 950 records identified, seven studies published between 2021 and 2026 met inclusion criteria. Four addressed prognosis or survival, two addressed diagnosis or early detection, and one addressed treatment‐receipt prediction. The best‐performing survival model achieved an AUROC of 0.89 (internal) and 0.81 (external validation), with a concordance index of 0.93. Other analyses suggested improved model fit or additional prognostic information beyond conventional AJCC staging, although direct comparisons of discrimination were not consistently available. A smartphone‐based diagnostic tool achieved an AUC of 0.80 for general malignant‐lesion triage, although sensitivity fell from 82.5% to 67.6% under a real‐world, STARD‐compliant worst‐case analysis; importantly, the cohort included only one MCC lesion, which both the CNN and teledermatology assessment classified as low risk, precluding meaningful MCC‐specific performance estimation. A blood‐based repertoire‐sequencing model reported near‐perfect discrimination but lacked independent MCC validation. Overall risk of bias was high, with the “analysis” domain most frequently downgraded; no study integrating multimodal data was identified. Conclusions: AI applications in MCC remain early stage but demonstrate meaningful potential to refine prognostic stratification beyond conventional staging, although MCC‐specific diagnostic evidence remains severely limited. Broader external validation and multimodal data integration represent the field’s most pressing needs before clinical translation is warranted.

Background: This study aimed to systematically review and analyze the available evidence on the safety and efficacy of physical activity (PA) in patients with HCM. Methods: We conducted a systematic search of PubMed, Cochrane, and Web of Science databases up to March 30, 2025. Fourteen studies (4 RCTs) were included in the qualitative synthesis and ten in the quantitative synthesis, totaling 10478 patients. Results: The meta-analysis demonstrated a significant improvement in peak VO₂ in the moderate intensity PA (MIPA) group, with a mean difference of 1.77 mL/kg/min (95% CI: 0.93 to 2.60, I² = 38.2%, p = 0.19), while changes in body mass index were not significant (MD: −0.66 kg/m²; 95% CI: −1.77 to 0.44; I² = 62%; p = 0.07). No significant differences were observed in the occurrence of non-sustained ventricular tachycardia (NSVT) (OR = 1.54, 95% CI: 0.93 to 2.52, I² = 28.3%, p = 0.24), atrial fibrillation (OR = 0.89, 95% CI: 0.77 to 1.03, I² = 28.6%, p = 0.23), or syncope (OR = 1.23, 95% CI: 0.72 to 2.10, I² = 25.6%, p = 0.24) between the MIPA and sedentary group. Additionally, the occurrence of NSVT between the high-intensity PA and MIPA group showed no significant difference (OR = 1.19, 95% CI: 0.60 to 2.36, I² = 0%, p = 0.99). Conclusion: The results suggest that regular exercise does not increase the risk of NSVT, AF, or syncope while enhancing peak VO₂, indicating that regular exercise is safe and beneficial in HCM patients.